Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300. doi:10.3389/fphar.2018.01300
   PubMed Web of Science ®Google Scholar
• Twelves C, Jove M, Gombos A, Awada A. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer. Crit Rev Oncol Hematol. 2016;100:74–87. doi:10.1016/j.critrevonc.2016.01.021
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–480. doi:10.1038/nrc2394
   PubMed Web of Science ®Google Scholar
• Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet. 2019;394(10200):793–804. doi:10.1016/S0140-6736(19)31774-X
   PubMed Web of Science ®Google Scholar
• Lambert JM, Berkenblit A. Antibody–drug conjugates for cancer treatment. Annu Rev Med. 2018;69(1):191–207. doi:10.1146/annurev-med-061516-121357
   PubMedGoogle Scholar
• Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4):100553. doi:10.1016/j.esmoop.2022.100553
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical pharmacology of antibody-drug conjugates. Antibodies Basel Switz. 2021;10(2):20. doi:10.3390/antib10020020
   PubMedGoogle Scholar
• Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825–2834. doi:10.1158/1535-7163.MCT-16-0408
   PubMed Web of Science ®Google Scholar
• García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res. 2018;78(9):2159–2165. doi:10.1158/0008-5472.CAN-17-3671
   PubMed Web of Science ®Google Scholar
• Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody–drug conjugates. Nat Rev Clin Oncol. 2024;21:1–21. doi:10.1038/s41571-023-00821-7
   PubMedGoogle Scholar
• Michel LL, Bermejo JL, Gondos A, Marmé F, Schneeweiss A. T-DM1 as a new treatment option for patients with metastatic HER2-positive breast cancer in clinical practice. Anticancer Res. 2015;35(9):5085–5090.
   PubMed Web of Science ®Google Scholar
• Boyraz B, Sendur MAN, Aksoy S, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin. 2013;29(4):405–414. doi:10.1185/03007995.2013.775113
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label Phase 3 trial. Lancet Oncol. 2017;18(6):743–754. doi:10.1016/S1470-2045(17)30313-3
   PubMed Web of Science ®Google Scholar
• Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2–positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141–148. doi:10.1200/JCO.2016.67.4887
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi:10.1016/S1470-2045(19)30863-0
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol off J Am Soc Clin Oncol. 2019;37(25):2206–2216. doi:10.1200/JCO.19.00882
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa1814017
   PubMed Web of Science ®Google Scholar
• Kowalczyk L, Bartsch R, Singer CF, Farr A. Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive breast cancer patients. Breast Care Basel Switz. 2017;12(6):401–408. doi:10.1159/000480492
   PubMed Web of Science ®Google Scholar
• Narayan P, Osgood CL, Singh H, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2021;27(16):4478–4485. doi:10.1158/1078-0432.CCR-20-4557
   PubMed Web of Science ®Google Scholar
• Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Ann Pharmacother. 2021;55(11):1410–1418. doi:10.1177/1060028021998320
   PubMed Web of Science ®Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–826. doi:10.1016/S1470-2045(19)30097-X
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• André F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;1:1.
   Google Scholar
• Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–117. doi:10.1016/S0140-6736(22)02420-5
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-breast01 subgroup analysis. Cancer Discov. 2022;12(12):2754–2762. doi:10.1158/2159-8290.CD-22-0837
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–1847. doi:10.1038/s41591-022-01935-8
   PubMed Web of Science ®Google Scholar
• Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro-Oncol. 2023;25(1):157–166. doi:10.1093/neuonc/noac144
   PubMed Web of Science ®Google Scholar
• Guo Z, Ding Y, Wang M, Liu J, Zhai Q, Du Q. Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study. J Clin Pharm Ther. 2022;47(11):1837–1844. doi:10.1111/jcpt.13777
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo, Inc. A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in participants with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05). clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04622319. Accessed February 19, 2024.
   Google Scholar
• AstraZeneca. A phase 3 open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) Monotherapy or T-DXd followed by thp compared to ddac-thp in participants with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT05113251. Accessed February 19, 2024.
   Google Scholar
• AstraZeneca. Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive, first-line metastatic breast cancer (DESTINY-Breast09). clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04784715. Accessed February 19, 2024.
   Google Scholar
• Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335–1344. doi:10.1080/10717544.2022.2069883
   PubMed Web of Science ®Google Scholar
• Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics. J Clin Oncol. 2017;35(15_suppl):1075. doi:10.1200/JCO.2017.35.15_suppl.1075
   Google Scholar
• Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol off J Am Soc Clin Oncol. 2017;35(19):2141–2148. doi:10.1200/JCO.2016.70.8297
   PubMed Web of Science ®Google Scholar
• Gustavson M, Haneder S, Spitzmueller A, et al. Abstract PD6-01: novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. Cancer Res. 2021;81(4_Supplement):1.
   Web of Science ®Google Scholar
• Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. doi:10.1038/s41523-022-00468-0
   PubMed Web of Science ®Google Scholar
• Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control CCC. 2009;20(7):1071–1082. doi:10.1007/s10552-009-9331-1
   PubMed Web of Science ®Google Scholar
• Wahby S, Fashoyin-Aje L, Osgood CL, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(7):1850–1854. doi:10.1158/1078-0432.CCR-20-3119
   PubMed Web of Science ®Google Scholar
• Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022;45(7):279–285. doi:10.1097/COC.0000000000000919
   PubMed Web of Science ®Google Scholar
• Weiss J, Glode A, Messersmith WA, Diamond J. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther. 2019;19(8):673–679. doi:10.1080/14737140.2019.1654378
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. doi:10.1056/NEJMoa2028485
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Narayan P, Dilawari A, Osgood C, et al. US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol off J Am Soc Clin Oncol. 2023;2023:JCO2202447.
   Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055
   PubMedGoogle Scholar
• Lobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–514. doi:10.1007/s10549-013-2711-y
   PubMed Web of Science ®Google Scholar
• Matutino A, Joy AA, Brezden-Masley C, Chia S, Verma S. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Curr Oncol Tor Ont. 2018;25(Suppl 1):1.
   Google Scholar
• McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract. 2022;18(5):319–327. doi:10.1200/OP.21.00384
   PubMedGoogle Scholar
• Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients With HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(24):2532–2537. doi:10.1200/JCO.2018.77.9777
   PubMed Web of Science ®Google Scholar
• Bardia A, Diamond JR, Vahdat LT, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J Clin Oncol. 2018;36(15_suppl):1004. doi:10.1200/JCO.2018.36.15_suppl.1004
   Web of Science ®Google Scholar
• Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365–3376. doi:10.1200/JCO.22.01002
   PubMed Web of Science ®Google Scholar
• Rugo HS, Bardia A, Marmé F, et al. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol. 2022;33:1.
   Web of Science ®Google Scholar
• Li BT, Michelini F, Misale S, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10(5):674–687. doi:10.1158/2159-8290.CD-20-0215
   PubMed Web of Science ®Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701. doi:10.1158/2159-8290.CD-19-1014
   PubMed Web of Science ®Google Scholar
• Heymach J, Negrao M, Robichaux J, et al. OA02.06 A Phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2018;13(10):S323–S324. doi:10.1016/j.jtho.2018.08.243
   PubMed Web of Science ®Google Scholar
• Venetis K, Crimini E, Sajjadi E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022;9. doi:10.3389/fmolb.2022.834651
   Web of Science ®Google Scholar
• Paige answers call to better identify breast cancer patients with low expression of HER2. 2022. Available from: https://www.businesswire.com/news/home/20220623005253/en/Paige-Answers-Call-to-Better-Identify-Breast-Cancer-Patients-with-Low-Expression-of-HER2. Accessed February 19, 2024.
   Google Scholar
• Moutafi M, Robbins CJ, Yaghoobi V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Investig J Tech Methods Pathol. 2022;102(10):1101–1108. doi:10.1038/s41374-022-00804-9
   PubMed Web of Science ®Google Scholar
• Kennedy JJ, Whiteaker JR, Kennedy LC, et al. Quantification of human epidermal growth factor receptor 2 by immunopeptide enrichment and targeted mass spectrometry in formalin-fixed paraffin-embedded and frozen breast cancer tissues. Clin Chem. 2021;67(7):1008–1018. doi:10.1093/clinchem/hvab047
   PubMed Web of Science ®Google Scholar
• Xu K, Bayani J, Mallon E, et al. Discordance between Immunohistochemistry and Erb-B2 receptor tyrosine kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer. J Mol Diagn JMD. 2022;24(7):775–783. doi:10.1016/j.jmoldx.2022.04.002
   PubMed Web of Science ®Google Scholar
• Hoffman-Censits JH, Lombardo KA, Parimi V, et al. Expression of nectin-4 in bladder urothelial carcinoma morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol AIMM. 2021;29(8):619–625. doi:10.1097/PAI.0000000000000938
   Web of Science ®Google Scholar
• Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol off J Eur Soc Med Oncol. 2021;32(9):1148–1156. doi:10.1016/j.annonc.2021.06.002
   PubMed Web of Science ®Google Scholar
• Chu CE, Sjöström M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res off J Am Assoc Cancer Res. 2021;27(18):5123–5130. doi:10.1158/1078-0432.CCR-20-4175
   PubMed Web of Science ®Google Scholar
• Hunter FW, Barker HR, Lipert B, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603–612. doi:10.1038/s41416-019-0635-y
   PubMed Web of Science ®Google Scholar
• Branco FP, Machado D, Silva FF, et al. Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am J Transl Res. 2019;11(9):6110–6116.
   PubMed Web of Science ®Google Scholar
• Li G, Guo J, Shen BQ, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 2018;17(7):1441–1453. doi:10.1158/1535-7163.MCT-17-0296
   PubMed Web of Science ®Google Scholar
• Sung M, Tan X, Lu B, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17(1):243–253. doi:10.1158/1535-7163.MCT-17-0403
   PubMed Web of Science ®Google Scholar
• Loibl S, Majewski I, Guarneri V, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol off J Eur Soc Med Oncol. 2016;27(8):1519–1525. doi:10.1093/annonc/mdw197
   PubMed Web of Science ®Google Scholar
• Baselga J, Lewis Phillips GD, Verma S, et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a phase iii study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22(15):3755–3763. doi:10.1158/1078-0432.CCR-15-2499
   PubMed Web of Science ®Google Scholar
• Kim SB, Wildiers H, Krop IE, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer. Int, J, Cancer. 2016;139(10):2336–2342. doi:10.1002/ijc.30276
   PubMed Web of Science ®Google Scholar
• Denkert C, Lambertini C, Fasching PA, et al. Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2023;29(8):1569–1581. doi:10.1158/1078-0432.CCR-22-1989
   PubMed Web of Science ®Google Scholar
• Mosele MF, Lusque A, Dieras VC, et al. LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. Ann Oncol. 2022;33:1.
   Google Scholar
• Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11(10):2436–2445. doi:10.1158/2159-8290.CD-21-0702
   PubMed Web of Science ®Google Scholar
• Beishenaliev A, Loke YL, Goh SJ, et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J Control Release off J Control Release Soc. 2023;359:268–286. doi:10.1016/j.jconrel.2023.05.032
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5(207):207ra144. doi:10.1126/scitranslmed.3006682
   PubMed Web of Science ®Google Scholar
• Fang S, Brems BM, Olawode EO, Miller JT, Brooks TA, Tumey LN. Design and characterization of immune-stimulating imidazo[4,5-c]quinoline antibody-drug conjugates. Mol Pharm. 2022;19(9):3228–3241. doi:10.1021/acs.molpharmaceut.2c00392
   PubMedGoogle Scholar
• Pillow TH, Adhikari P, Blake RA, et al. Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem. 2020;15(1):17–25. doi:10.1002/cmdc.201900497
   PubMed Web of Science ®Google Scholar
• Tang C, Zeng Y, Zhang J, et al. One-Pot assembly of dual-site-specific antibody-drug conjugates via glycan remodeling and affinity-directed traceless conjugation. Bioconjug Chem. 2023. doi:10.1021/acs.bioconjchem.3c00048
   Web of Science ®Google Scholar
• Xu Z, Guo D, Jiang Z, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682. doi:10.1016/j.ejmech.2019.111682
   PubMed Web of Science ®Google Scholar
• QuantumLeap Healthcare Collaborative. ISPY-P1.01: evaluating the safety of weekly paclitaxel with trastuzumab duocarmazine (SYD985) in patients with metastatic cancer: a Phase I/Ib Trial. clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04602117. Accessed February 19, 2024.
   Google Scholar
• Byondis BV. A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03262935. Accessed February 19, 2024.
   Google Scholar
• Jhaveri K, Han H, Dotan E, et al. 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol. 2022;33:S749–50. doi:10.1016/j.annonc.2022.07.589
   Web of Science ®Google Scholar
• Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol. 2021;39(15_suppl):1.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Liu R, et al. Phase I Study of A166, a novel antibody-drug conjugate in advanced HER2-expressing solid tumors. In Review; 2022. Available from: https://www.researchsquare.com/article/rs-2179560/v1. Accessed February 19, 2024.
   Google Scholar
• Hamilton EP, Barve MA, Bardia A, et al. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. J Clin Oncol. 2018;36(15_suppl):2546. doi:10.1200/JCO.2018.36.15_suppl.2546
   Web of Science ®Google Scholar
• SCRI Development Innovations, LLC. A Phase II Study of U3-1402 in patients with metastatic breast cancer. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04699630. Accessed February 19, 2024.
   Google Scholar
• Daiichi Sankyo Co., Ltd. Phase 1, two-part, multicenter, open-label, multiple dose, first-in-human study of DS-1062a in subjects with advanced solid Tumors (TROPION-PanTumor01). clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03401385. Accessed February 19, 2024.
   Google Scholar
• AstraZeneca. A Phase IB/II, 2-stage, Open-label, multicenter study to determine the efficacy and safety of durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in combination with novel oncology therapies with or without paclitaxel for first-line metastatic triple negative breast cancer. clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT03742102. Accessed February 19, 2024.
   Google Scholar
• AstraZeneca. A phase 3, open-label, randomised study of datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients who are not candidates for PD-1/PD-L1 inhibitor therapy in first-line locally recurrent inoperable or metastatic triple-negative breast cancer (TROPION Breast02). clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05374512. Accessed February 19, 2024.
   Google Scholar
• Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. A randomized, controlled, open-label, multi-center phase iii clinical trial of skb264 for injection versus investigator selected regimens in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05347134. Accessed February 19, 2024.
   Google Scholar
• Cortés J, Diab S, Basho RK, et al. 357TiP SGNLVA-002: single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. Ann Oncol. 2020;31:S393. doi:10.1016/j.annonc.2020.08.459
   Google Scholar
• Modi S, Pusztai L, Forero A, et al. Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res. 2018;78(4_Supplement):PD3–14. doi:10.1158/1538-7445.SABCS17-PD3-14
   Web of Science ®Google Scholar
• Seagen Inc. Single arm, open label phase 1b/2 Study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03310957. Accessed February 19, 2024.
   Google Scholar
• PharmD BP. FDA to Review [Vic-]Trastuzumab Duocarmazine for HER2-positive metastatic breast cancer. MPR. 2022. Available from: https://www.empr.com/home/news/drugs-in-the-pipeline/fda-to-review-vic-trastuzumab-duocarmazine-for-her2-positive-metastatic-breast-cancer/. Accessed February 19, 2024.
   Google Scholar
• QuantumLeap Healthcare Collaborative. ISPY-P1.01: evaluating the safety of weekly paclitaxel with trastuzumab duocarmazine (syd985) in patients with metastatic cancer: a phase I/Ib trial. clinicaltrials.gov; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04602117. Accessed February 19, 2024.
   Google Scholar
• Shenderov E, Mallesara GHG, Wysocki PJ, et al. 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion. Ann Oncol. 2021;32:S657–9. doi:10.1016/j.annonc.2021.08.1133
   Web of Science ®Google Scholar
• BioAtla, Inc. A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, alone and in combination with a pd-1 inhibitor, in patients with advanced solid tumors (Ph1) and Melanoma and NSCLC Patients (Ph2). clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03504488. Accessed February 19, 2024.
   Google Scholar
• Sanofi. Open-label, multi-cohort, phase 2 trial, evaluating the efficacy and safety of tusamitamab ravtansine (SAR408701) monotherapy and in combination in patients with CEACAM5-positive advanced solid tumors. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04659603. Accessed February 19, 2024.
   Google Scholar
• Eisai Inc. A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in subjects with selected tumor types. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04300556. Accessed February 19, 2024.
   Google Scholar
• Guo P, Huang J, Zhu B, et al. A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023;9(18):eabq7866. doi:10.1126/sciadv.abq7866
   PubMed Web of Science ®Google Scholar